A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Elixiron Immunotherapeutics (Hong Kong) Ltd.
The University of Hong Kong
University of Thessaly
NRG Oncology
University of Massachusetts, Amherst
Northwestern University
Korea University
Wake Forest University Health Sciences
University of California, Irvine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Northwestern University
Alzheimer's Prevention and Reversal Project, Inc.
University Hospital, Rouen
Duke University
Cognito Therapeutics, Inc.
University of Texas at Austin
University of Texas at Austin
Centre Hospitalier de Valenciennes
The Hospital for Sick Children
Ottawa Hospital Research Institute
University of Cincinnati
Flint Rehabilitation Devices, LLC
University of Alabama at Birmingham
University of Rochester
Brigham and Women's Hospital
Dartmouth-Hitchcock Medical Center
Mayo Clinic
Aarhus University Hospital
Centre Francois Baclesse
UNC Lineberger Comprehensive Cancer Center
Endeavor Health
Stanford University
LanZhou University
Ellis Medicine
Sir Run Run Shaw Hospital, Qingchun Campus, Zhejiang University School of Medicine,
Anhui Medical University
University of Santiago de Compostela
The Hospital for Sick Children
University of Rochester
National Taiwan University Hospital
Massachusetts General Hospital
Ohio State University
NRG Oncology
University of Alabama at Birmingham
Memorial University of Newfoundland
University of Liege
University Medicine Greifswald
Universidad de Córdoba
University of Washington
Appalachian State University